JDRF Statement on Lilly $35 Co-pay Card for Insulin in Response to COVID-19 Crisis
At JDRF, we welcome Lilly’s decision to introduce a co-pay card that allows anyone using commercial insurance, as well as those without any insurance, to purchase their monthly prescription of Lilly insulin for $35 or less in out-of-pocket costs.
For people with type 1 diabetes (T1D), insulin is a life-saving drug that no one should ever have to ration or go without. No one should die because they can’t afford their insulin. The economic repercussions of the COVID-19 pandemic make insulin access and affordability more important than ever.
JDRF has long advocated for affordable and predictable out-of-pocket costs of insulin. We’re urging other insulin manufacturers to take immediate actions like the one Lilly has announced, and to also develop long-term solutions that last beyond the current crisis.
JDRF will continue to urge insulin manufacturers, health plans, employers, and policymakers to create long-term solutions that make out-of-pocket insulin costs low and predictable so that people with T1D have the insulin they need to stay as healthy as possible while we work urgently to develop cures.
For information and resources on how to manage T1D during the COVID-19 pandemic, visit jdrf.org/coronavirus. JDRF also provides information and resources at jdrf.org/costs to help people access and pay for insulin and other prescriptions.